Skip to main content
SpringerLink
Log in

Use of Bisphosphonates in Hematology

  • Chapter
  • First Online:
Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach

Abstract

Bisphosphonates (BPs) are used in the treatment of bone diseases associated with hematologic pathologies. BP therapy is, in fact, the mainstay of treatment for bone disease in multiple myeloma (MM) patients. These drugs decrease the frequency and delay the development of skeletal events in MM. Moreover BPs are used for the treatment of the malignancy-associated hypercalcemia seen in patients with blood diseases, such as MM and adult T-cell leukemia/lymphoma. Finally, an anti-tumor effect of BPs in MM patients has been described. However, BP-induced osteonecrosis of the jaw (BIONJ) is an unremitting adverse outcome. This chapter reviews the current theories explaining the mechanism for this complication. We report evidence for the use of BPs in hematologic diseases and provide recommendations to guide the clinical practice of treating bone disease in hematologic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Holmberg AR, Lerner UH, Alayia AA et al (2010) Development of a novel poly bisphosphonate conjugate for treatment of skeletal metastasis and osteoporosis. J Oncol 37(3):563–567

    CAS  Google Scholar 

  2. Levy J, Roodman GD (2009) The role of bisphosphonates in multiple myeloma. Curr Hematol Malig Rep 4(2):108–112

    Article  PubMed  Google Scholar 

  3. Melton LJ 3rd, Kyle RA, Achenbach SJ et al (2005) Fracture risk with multiple myeloma: a population based study. J Bone Miner Res 20:487–493

    Article  PubMed  Google Scholar 

  4. Mahnken AH, Wildberger JE, Gehbauer G et al (2002) Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR 178:1429–1436

    PubMed  CAS  Google Scholar 

  5. Terpos E, Berenson J, Cook RJ et al (2010) Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 24(5):1043–1049

    Article  PubMed  CAS  Google Scholar 

  6. Saad F, Lipton A, Cook R et al (2007) Pathological fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860–1867

    Article  PubMed  Google Scholar 

  7. Silvestris F, Cafforio P, Calvani N et al (2004) Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 126(4):475–486

    Article  PubMed  Google Scholar 

  8. Tian E, Zhan F, Walker R et al (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349(26):2483–2494

    Article  PubMed  CAS  Google Scholar 

  9. Oshima T, Abe M, Asano J et al (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106(9):3160–3165

    Article  PubMed  CAS  Google Scholar 

  10. Giuliani N, Colla S, Morandi F et al (2005) Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106(7):2472–2483

    Article  PubMed  CAS  Google Scholar 

  11. Ehrlich LA, Chung HY, Ghobrial I et al (2005) IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 106(4):1407–1414

    Article  PubMed  CAS  Google Scholar 

  12. Franchimont N, Rydziel S, Canalis E (2000) Transforming growth factor-beta increases interleukin-6 transcripts in osteoblasts. Bone 26(3):249–253

    Article  PubMed  CAS  Google Scholar 

  13. Hayashi T, Hideshima T, Nguyen AN et al (2004) Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 10(22):7540–7546

    Article  PubMed  CAS  Google Scholar 

  14. Silvestris F, Cafforio P, Tucci M et al (2003) Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol 122(1):39–52

    Article  PubMed  CAS  Google Scholar 

  15. Sati HIA, Greaves M, Apperley JF et al (1999) Expression of interleukin-1b and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br J Haematol 104(2):350–357

    Article  PubMed  CAS  Google Scholar 

  16. Roux S, Mariette X (2004) The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-Kb) and RANK ligand expression. Leuk Lymphoma 45(6):1111–1118

    Article  PubMed  CAS  Google Scholar 

  17. Oyajobi BO, Mundy GR (2003) Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. Cancer 97(3):813–817

    Article  PubMed  Google Scholar 

  18. Mitsiades CS, Mitsiades N, Hideshima T et al (2006) Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets 7(10):1341–1347

    Article  PubMed  CAS  Google Scholar 

  19. Tanaka Y, Abe M, Hiasa M et al (2007) Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13(3):816–823

    Article  PubMed  CAS  Google Scholar 

  20. Vogel CL, Yanagihara RH, Wood AJ et al (2004) Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9(6):687–695

    Article  PubMed  CAS  Google Scholar 

  21. Gralow J, Tripathy D (2007) Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage 33(4):462–472

    Article  PubMed  CAS  Google Scholar 

  22. Ludwig H, Zojer N (2007) Supportive care in multiple myeloma. Best Pract Res Clin Haematol. 20(4):817–835

    Article  PubMed  Google Scholar 

  23. Dunstan C, Felsenberg D, Seibel MJ (2006) Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 4(1):42–55

    Article  CAS  Google Scholar 

  24. Diel IJ, Bergner R, Grotz KA (2007) Adverse effects of bisphosphonates: current issues. J Support Oncol 5:475–482

    PubMed  CAS  Google Scholar 

  25. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117

    Article  PubMed  Google Scholar 

  26. Walter C, Grotz KA, Kunkel M et al (2007) Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15:197–202

    Article  PubMed  Google Scholar 

  27. Nastro E, Musolino C, Allegra A et al (2007) Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol 117:181–187

    Article  PubMed  CAS  Google Scholar 

  28. Nastro E, Allegra A, Oteri G et al (2009) Avascular necrosis of bone in leukemia and osteonecrosis of jaw by bisphosphonate. J Oral Maxillofac Surg 67(12):2701–2703

    Article  PubMed  Google Scholar 

  29. Badros A, Weikel D, Salama A et al (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945–952

    Article  PubMed  CAS  Google Scholar 

  30. Calvo-Villas JM, Tapia Torres M, Govantes Rodríguez J et al (2006) Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid. Med Clin (Barc) 127:576–579

    Article  Google Scholar 

  31. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91:968–971

    PubMed  CAS  Google Scholar 

  32. Tosi P, Zamagni E, Cangini D et al (2006) Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 108:3951–3952

    Article  PubMed  CAS  Google Scholar 

  33. Zervas K, Verrou E, Teleioudis Z et al (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134:620–623

    Article  PubMed  CAS  Google Scholar 

  34. Corso A, Varettoni M, Zappasodi P et al (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21:1545–1548

    Article  PubMed  CAS  Google Scholar 

  35. Petrucci MT, Gallucci C, Agrillo A et al (2007) Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. Haematologica 92:1289–1290

    Article  PubMed  Google Scholar 

  36. Walter C, Al-Nawas B, Frickhofen N et al (2010) Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 6:11

    Article  PubMed  CAS  Google Scholar 

  37. Woo SB, Hellstein JW, Kalmar JR (2006) Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761

    PubMed  CAS  Google Scholar 

  38. Van den Wyngaert T, Huizing MT, Vermorken JB (2007) Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 19:315–322

    Article  PubMed  CAS  Google Scholar 

  39. Mehrotra B, Ruggiero S (2006) Bisphosphonate complications including osteonecrosis of the jaw. Hematology 2006:356–360

    Article  Google Scholar 

  40. Helstein JW, Cindy MS, Cindy L et al (2005) Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63:682–689

    Article  Google Scholar 

  41. Ardine M, Generali D, Donadio M (2006) Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol 17:1336–1337

    Article  PubMed  CAS  Google Scholar 

  42. Padbury AD Jr, Tözüm TF, Taba M Jr et al (2006) The impact of primary hyperparathyroidism on the oral cavity. J Clin Endocrinol Metab 91:3439–3445

    Article  PubMed  CAS  Google Scholar 

  43. Phal PM, Myall RWT, Assael LA et al (2007) Imaging findings of bisphosphonate-associated osteonecrosis of the jaw. Am J Neuroradiol 28:1139–1145

    Article  PubMed  CAS  Google Scholar 

  44. Fournier P, Boissier S, Filleur S et al (2002) bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544

    PubMed  CAS  Google Scholar 

  45. Wood J, Bonjean K, Ruetz S et al (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061

    Article  PubMed  CAS  Google Scholar 

  46. Wood J, Schnell C, Green JR (2000) Zoledronic acid, a potent inhibitor of bone resorption, inhibits proliferation and induces apoptosis in human endothelial cells in vitro and is anti-angiogenic in a murine growth factor implant model. Proc Am Soc Clin Oncol 665:664–665

    Google Scholar 

  47. Santini D, Vincenzi B, Avvisati G et al (2002) Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 8:1080–1084

    PubMed  CAS  Google Scholar 

  48. Vincenzi B, Santini D, Rocci L et al (2003) Bisphosphonates: new antiangiogenic molecules in cancer treatment? Ann Oncol 14:806–807

    Article  PubMed  CAS  Google Scholar 

  49. Ferretti G, Fabi A, Carlini P et al (2005) Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69:35–43

    Article  PubMed  CAS  Google Scholar 

  50. Alonci A, Allegra A, Bellomo G et al (2007) Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothelial growth factor receptor 1. Leuk Lymphoma 48(9):1852–1854

    Article  PubMed  CAS  Google Scholar 

  51. Allegra A, Oteri G, Nastro E et al (2007) Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 25:164–169

    Article  PubMed  CAS  Google Scholar 

  52. Ziebart T, Pabst A, Klein MO et al (2011) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Invest 15:105–111

    Article  Google Scholar 

  53. Pruneti G, Ponzoni M, Ferreri A et al (2002) Microvessel density, a surrogate marker of angiogenesis, is significantly related to serviva in multiple myeloma patients. Br J Haematol 118:817–820

    Article  Google Scholar 

  54. Zhang H, Vakil V, Braunstein M et al (2005) Circulating endothelial progenitor cells in multiple myeloma: implication and significance. Blood 105:3286–3294

    Article  PubMed  CAS  Google Scholar 

  55. Allegra A, Alonci A, Penna G et al (2010) Bisphosphonate induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with Bisphosphonate-induced Osteonecrosis of the jaws. Acta Haematol 124(2):79–85

    Article  PubMed  CAS  Google Scholar 

  56. Estilo CL, Fornier M, Farooki A et al (2008) Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 26(24):4037–4038

    Article  PubMed  Google Scholar 

  57. Ayllon J, Launay-Vacher V, Medioni J et al (2009) Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol 20(3):600–601

    Article  PubMed  CAS  Google Scholar 

  58. Walker BA, Leone PE, Jenner MW et al (2006) Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 108:1733–1743

    Article  PubMed  CAS  Google Scholar 

  59. Sarasquete ME, Garcıa-Sanz R, Marın L et al (2008) Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112:2709–2712

    Article  PubMed  CAS  Google Scholar 

  60. Ingelman-Sundberg M, Sim SC, Gomez A et al (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526

    Article  PubMed  CAS  Google Scholar 

  61. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP2C8 allele nomenclature. http://www.cypalleles.ki.se/cyp2c8.htm. Accessed 11 May 2008

  62. Fleming I (2007) Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat 82:60–67

    Article  PubMed  CAS  Google Scholar 

  63. Capdevila JH, Falck JR, Harris RC (2000) Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41:163–181

    PubMed  CAS  Google Scholar 

  64. Luckman SP, Hughes DE, Coxon FP et al (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589

    Article  PubMed  CAS  Google Scholar 

  65. Anderson K, Alsina M, Bensinger W et al (2007) National Comprehensive Cancer Network (NCCN). Multiple myeloma guidelines. J Natl Compr Canc Netw 5:118

    PubMed  CAS  Google Scholar 

  66. Kyle RA, Yee GC, Somerfield MR et al (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25(17):2464–2472

    Article  PubMed  CAS  Google Scholar 

  67. Lacy MQ, Dispenzieri A, Gertz MA et al (2006) Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81(8):1047–1053

    Article  PubMed  CAS  Google Scholar 

  68. Harrouseau JL, Greil R, Kloke O (2005) ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of multiple myeloma. Ann Oncol 16(1):i45–i47

    Article  PubMed  Google Scholar 

  69. Durie BG (2007) Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc 82(4):516–517

    Article  PubMed  Google Scholar 

  70. Chern B, Joseph D, Joshua D et al (2004) Bisphosphonate infusions: patient preference, safety and clinic use. Support Care Cancer 12(6):463–466

    Article  PubMed  CAS  Google Scholar 

  71. Terpos E, Sezer P, Garcia-Sanz et al (2009) The use of bisphosphonates in multiple myeloma: recommendations o fan expert panel on behalf of the European Myeloma Network. Ann Oncol 20(8):1303–1317

    Google Scholar 

  72. Cafro AM, Barbarano L, Nosari AM et al (2008) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid. Clin Lymphoma Myeloma 8(2):111–116

    Article  PubMed  CAS  Google Scholar 

  73. Ruggiero S, Gralow J, Marx RE (2006) Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2:7–14

    Article  PubMed  Google Scholar 

  74. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws, September 25, 2006 http://www.aaoms.org/docs/position_papers/osteonecrosis.pdf

  75. Hansen T, Kunkel M, Weber A, James Kirkpatrick C (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates—histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35(3):155–160

    Article  PubMed  Google Scholar 

  76. Weitzman R, Sauter N, Eriksen EF et al (2007) Critical review: updated recommendations for the prevention, diagnosis, treatment of osteonecrosis of the jaw in cancer patients—May 2006. Crit Rev Oncol Hematol 62(2):148–152

    Article  PubMed  Google Scholar 

  77. Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34):8580–8587

    Article  PubMed  Google Scholar 

  78. Melo MD, Obeid G (2005) Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 136(12):1675–1681

    PubMed  CAS  Google Scholar 

  79. Ruggiero SL, Mehrotra B, Rosenberg TJ et al (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62(5):527–534

    Article  PubMed  Google Scholar 

  80. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91(7):968–971

    PubMed  CAS  Google Scholar 

  81. Zervas K, Verrou E, Teleioudis Z et al (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134(6):620–623

    Article  PubMed  CAS  Google Scholar 

  82. Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353(1):99–102

    Article  PubMed  CAS  Google Scholar 

  83. Mehrotra B, Ruggiero S (2006) Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program 356-360

    Google Scholar 

  84. Montazeri AH, Erskine JG, McQuaker IG (2007) Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 79(1):69–71

    Article  PubMed  Google Scholar 

  85. Brooks JK, Gilson AJ, Sindler AJ et al (2007) Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103(6):780–786

    Article  PubMed  Google Scholar 

  86. Yarom N, Yahalom R, Shoshani Y et al (2007) Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18(10):1363–1370

    Article  PubMed  CAS  Google Scholar 

  87. Mavrokokki T, Cheng A, Stein B et al (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65(3):415–423

    Article  PubMed  Google Scholar 

  88. Corso A, Varettoni M, Zappasodi P et al (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21(7):1545–1548

    Article  PubMed  CAS  Google Scholar 

  89. Adam Z, Kozumplikova M, Pour L et al (2006) Osteonecrosis of the jaw in the course of multiple myeloma treatment and bisphosphonate administration. Vnitr Lek 52(2):176–180

    PubMed  CAS  Google Scholar 

  90. Badros A, Terpos E, Katodritou E et al (2008) Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 26(36):5904–5909

    Article  PubMed  Google Scholar 

  91. Coleman RE, Major P, Lipton A et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23(22):4925–4935

    Article  PubMed  CAS  Google Scholar 

  92. Attal M, Harousseau JL, Leyvraz S et al (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10):3289–3294

    Article  PubMed  CAS  Google Scholar 

  93. Montefusco V, Gay F, Spina F et al (2008) Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 49(11):2156–2162

    Article  PubMed  CAS  Google Scholar 

  94. Dickinson M, Prince HM, Kirsa S et al (2009) Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Intern Med J 39(5):304–316

    Article  PubMed  CAS  Google Scholar 

  95. McClune BL, Polgreen LE, Burmeister LA et al (2010) Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant. Aug 23. [Epub ahead of print]

    Google Scholar 

  96. Chae YS, Kim JG, Moon JH et al (2009) Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients. Bone Marrow Transplant 44(1):35–41

    Article  PubMed  CAS  Google Scholar 

  97. Sargent JT, Smith OP (2010) Haematological emergencies managing hypercalcaemia in adults and children with haematological disorders. Br J Haematol 149(4):465–477

    Article  PubMed  CAS  Google Scholar 

  98. Schmid I, Stachel D, Schön C et al (2001) Pamidronate and calcitonin as therapy of acute cancer-related hypercalcemia in children. Klinische Padiatrie 213(1):30–34

    Article  PubMed  CAS  Google Scholar 

  99. Goldbloom EB, Cummings EA, Yhap M (2005) Osteoporosis at presentation of childhood ALL: management with pamidronate. Pediatr Hematol Oncol 22(7):543–550

    Article  PubMed  Google Scholar 

  100. Yaccoby S, Pearse RN, Johnson CL et al (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116(2):278–290

    Article  PubMed  Google Scholar 

  101. Yaccoby S, Wezeman MJ, Zangari M et al (2006) Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 91(2):192–199

    PubMed  CAS  Google Scholar 

  102. Croucher PI, De Hendrik R, Perry MJ et al (2003) Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18(3):482–492

    Article  PubMed  CAS  Google Scholar 

  103. Dhodapkar MV, Singh J, Mehta J et al (1998) Anti-myeloma activity of pamidronate in vivo. Br J Haematol 103(2):530–532

    Article  PubMed  CAS  Google Scholar 

  104. Kondo H, Mori A (2002) Anti-tumor activity of pamidronate in human multiple myeloma. Leuk Lymphoma 43(4):919–921

    Article  PubMed  Google Scholar 

  105. Santini D, Virzi V, Fratto ME et al (2010) Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Curr Cancer Drug Targets 10(1):46–54

    Article  PubMed  CAS  Google Scholar 

  106. Koizumi M, Nakaseko C, Ohwada C et al (2007) Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells. Eur J Haematol 79(5):382–391

    Article  PubMed  CAS  Google Scholar 

  107. Guenther A, Gordon S, Tiemann M et al (2010) The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 126(1):239–246

    Article  PubMed  CAS  Google Scholar 

  108. Huang HM, Ding RS, Xiang XX, Hou J (2009) Effect of zoledronic acid on the growth and CD138 expression of myeloma cell line KM3. Zhonghua Xue Ye Xue Za Zhi 30(3):183–185

    PubMed  Google Scholar 

  109. Abe Y, Muto M, Nieda M et al (2009) Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 37(8):956–968

    Article  PubMed  CAS  Google Scholar 

  110. Schulman KL, Kohles J (2007) Economic burden of metastatic bone disease in the U. S. Cancer 109:2334–2342

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, University of Messina, Messina, Italy

    Caterina Musolino & Alessandro Allegra

Authors
  1. Caterina Musolino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Allegra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caterina Musolino .

Editor information

Editors and Affiliations

  1. , Dental Department, University of Messina, Via Consolare Valeria 1, Messina, 98100, Italy

    Francesco Saverio De Ponte

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Milan

About this chapter

Cite this chapter

Musolino, C., Allegra, A. (2012). Use of Bisphosphonates in Hematology. In: De Ponte, F. (eds) Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach. Springer, Milano. https://doi.org/10.1007/978-88-470-2083-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2083-2_4

  • Published:

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-2082-5

  • Online ISBN: 978-88-470-2083-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation